Vertex Pharmaceuticals IncorporatedVRTXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank71
3Y CAGR+16.6%
5Y CAGR+3.0%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+16.6%/yr
vs +0.1%/yr prior
5Y CAGR
+3.0%/yr
Recent acceleration
Acceleration
+16.5pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
1.2x
Modest growth
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 19.72% |
| 2024 | 28.83% |
| 2023 | 20.31% |
| 2022 | 12.45% |
| 2021 | 9.03% |
| 2020 | 17.01% |
| 2019 | 18.09% |
| 2018 | 12.40% |
| 2017 | 14.61% |
| 2016 | 14.78% |